Misonix to Present at the 40th Annual Canaccord Genuity Growth Conference

Rhea-AI Summary

Misonix, Inc. (Nasdaq: MSON) will participate in the 40th Annual Canaccord Genuity Growth Conference. The presentation will take place virtually on August 12 at 10:30 a.m. ET, featuring CEO Stavros Vizirgianakis and CFO Joe Dwyer. Investors can engage in one-on-one virtual meetings on August 12 and 13.

Misonix specializes in minimally invasive ultrasonic medical devices for surgical applications and wound care. The company is dedicated to enhancing clinical outcomes through innovative technology.

FARMINGDALE, N.Y., July 30, 2020 (GLOBE NEWSWIRE) -- Misonix, Inc. (Nasdaq: MSON), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced that it will be participating in the 40^th Annual Canaccord Genuity Growth Conference. Misonix Chief Executive Officer, Stavros Vizirgianakis, along with Joe Dwyer, Misonix Chief Financial Officer, will be making a virtual company presentation on Wednesday, August 12^th at 10:30 a.m. ET. Management will also be available to speak with institutional investors in one-on-one virtual meetings throughout the day on August 12^th and 13^th.

If you have questions about Misonix or are interested in conducting a conference call or meeting with management, please contact the Company’s investor relations firm, JCIR, at (212) 835-8500 or via email at mson@jcir.com.

About Misonix, Inc.

Misonix, Inc. (Nasdaq: MSON) designs, manufactures and markets minimally invasive ultrasonic medical devices used for precise bone sculpting, removal of soft and hard tumors and tissue debridement, primarily in the areas of neurosurgery, orthopedic surgery, plastic surgery, wound care and maxillo-facial surgery. The Company combined its SonicOne wound debridement application with its recently acquired TheraSkin product, a leading cellular skin substitute indicated for all wound treatments. The Company’s sales force operates as two divisions, Surgical (Neuro and Spine Applications) and Wound. At Misonix, Better Matters to us. That is why throughout the Company’s history, Misonix has maintained its commitment to medical technology innovation and the development of products that radically improve patient outcomes. Additional information is available on the Company's web site at www.misonix.com.

Contact:   
Joe Dwyer                                                                                               
Chief Financial Officer                                                                                        
Misonix, Inc.                                                                                            
631-927-9113

Norberto Aja, Jennifer Neuman
JCIR
212-835-8500 or mson@jcir.com

FAQ

When will Misonix present at the Canaccord Genuity Growth Conference?

Misonix will present on August 12, 2020, at 10:30 a.m. ET.

Who will represent Misonix at the conference?

CEO Stavros Vizirgianakis and CFO Joe Dwyer will represent Misonix.

What is Misonix's stock symbol?

The stock symbol for Misonix is MSON.

When are the one-on-one meetings with Misonix management scheduled?

One-on-one meetings are scheduled for August 12 and 13, 2020.

What products does Misonix specialize in?

Misonix specializes in minimally invasive ultrasonic medical devices for neurosurgery, orthopedic surgery, wound care, and more.